These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 32445698)

  • 1. Metabolic Regulation of the Epigenome Drives Lethal Infantile Ependymoma.
    Michealraj KA; Kumar SA; Kim LJY; Cavalli FMG; Przelicki D; Wojcik JB; Delaidelli A; Bajic A; Saulnier O; MacLeod G; Vellanki RN; Vladoiu MC; Guilhamon P; Ong W; Lee JJY; Jiang Y; Holgado BL; Rasnitsyn A; Malik AA; Tsai R; Richman CM; Juraschka K; Haapasalo J; Wang EY; De Antonellis P; Suzuki H; Farooq H; Balin P; Kharas K; Van Ommeren R; Sirbu O; Rastan A; Krumholtz SL; Ly M; Ahmadi M; Deblois G; Srikanthan D; Luu B; Loukides J; Wu X; Garzia L; Ramaswamy V; Kanshin E; Sánchez-Osuna M; El-Hamamy I; Coutinho FJ; Prinos P; Singh S; Donovan LK; Daniels C; Schramek D; Tyers M; Weiss S; Stein LD; Lupien M; Wouters BG; Garcia BA; Arrowsmith CH; Sorensen PH; Angers S; Jabado N; Dirks PB; Mack SC; Agnihotri S; Rich JN; Taylor MD
    Cell; 2020 Jun; 181(6):1329-1345.e24. PubMed ID: 32445698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular heterogeneity and CXorf67 alterations in posterior fossa group A (PFA) ependymomas.
    Pajtler KW; Wen J; Sill M; Lin T; Orisme W; Tang B; Hübner JM; Ramaswamy V; Jia S; Dalton JD; Haupfear K; Rogers HA; Punchihewa C; Lee R; Easton J; Wu G; Ritzmann TA; Chapman R; Chavez L; Boop FA; Klimo P; Sabin ND; Ogg R; Mack SC; Freibaum BD; Kim HJ; Witt H; Jones DTW; Vo B; Gajjar A; Pounds S; Onar-Thomas A; Roussel MF; Zhang J; Taylor JP; Merchant TE; Grundy R; Tatevossian RG; Taylor MD; Pfister SM; Korshunov A; Kool M; Ellison DW
    Acta Neuropathol; 2018 Aug; 136(2):211-226. PubMed ID: 29909548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EZHIP/CXorf67 mimics K27M mutated oncohistones and functions as an intrinsic inhibitor of PRC2 function in aggressive posterior fossa ependymoma.
    Hübner JM; Müller T; Papageorgiou DN; Mauermann M; Krijgsveld J; Russell RB; Ellison DW; Pfister SM; Pajtler KW; Kool M
    Neuro Oncol; 2019 Jul; 21(7):878-889. PubMed ID: 30923826
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Into Thin Air: Hypoxia Drives Metabolic and Epigenomic Deregulation of Lethal Pediatric Ependymoma.
    Englinger B; Hack OA; Filbin MG
    Dev Cell; 2020 Jul; 54(2):134-136. PubMed ID: 32693052
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunohistochemical analysis of H3K27me3 demonstrates global reduction in group-A childhood posterior fossa ependymoma and is a powerful predictor of outcome.
    Panwalkar P; Clark J; Ramaswamy V; Hawes D; Yang F; Dunham C; Yip S; Hukin J; Sun Y; Schipper MJ; Chavez L; Margol A; Pekmezci M; Chung C; Banda A; Bayliss JM; Curry SJ; Santi M; Rodriguez FJ; Snuderl M; Karajannis MA; Saratsis AM; Horbinski CM; Carret AS; Wilson B; Johnston D; Lafay-Cousin L; Zelcer S; Eisenstat D; Silva M; Scheinemann K; Jabado N; McNeely PD; Kool M; Pfister SM; Taylor MD; Hawkins C; Korshunov A; Judkins AR; Venneti S
    Acta Neuropathol; 2017 Nov; 134(5):705-714. PubMed ID: 28733933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. H3 K27M mutations are extremely rare in posterior fossa group A ependymoma.
    Ryall S; Guzman M; Elbabaa SK; Luu B; Mack SC; Zapotocky M; Taylor MD; Hawkins C; Ramaswamy V
    Childs Nerv Syst; 2017 Jul; 33(7):1047-1051. PubMed ID: 28623522
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EZHIP: a new piece of the puzzle towards understanding pediatric posterior fossa ependymoma.
    Jenseit A; Camgöz A; Pfister SM; Kool M
    Acta Neuropathol; 2022 Jan; 143(1):1-13. PubMed ID: 34762160
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence of H3 K27M mutations in posterior fossa ependymomas.
    Gessi M; Capper D; Sahm F; Huang K; von Deimling A; Tippelt S; Fleischhack G; Scherbaum D; Alfer J; Juhnke BO; von Hoff K; Rutkowski S; Warmuth-Metz M; Chavez L; Pfister SM; Pietsch T; Jones DT; Sturm D
    Acta Neuropathol; 2016 Oct; 132(4):635-7. PubMed ID: 27539613
    [No Abstract]   [Full Text] [Related]  

  • 9. EZHIP is a specific diagnostic biomarker for posterior fossa ependymomas, group PFA and diffuse midline gliomas H3-WT with EZHIP overexpression.
    Antin C; Tauziède-Espariat A; Debily MA; Castel D; Grill J; Pagès M; Ayrault O; Chrétien F; Gareton A; Andreiuolo F; Lechapt E; Varlet P
    Acta Neuropathol Commun; 2020 Nov; 8(1):183. PubMed ID: 33153494
    [No Abstract]   [Full Text] [Related]  

  • 10. Common molecular features of H3K27M DMGs and PFA ependymomas map to hindbrain developmental pathways.
    Pun M; Pratt D; Nano PR; Joshi PK; Jiang L; Englinger B; Rao A; Cieslik M; Chinnaiyan AM; Aldape K; Pfister S; Filbin MG; Bhaduri A; Venneti S
    Acta Neuropathol Commun; 2023 Feb; 11(1):25. PubMed ID: 36759899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lowered H3K27me3 and DNA hypomethylation define poorly prognostic pediatric posterior fossa ependymomas.
    Bayliss J; Mukherjee P; Lu C; Jain SU; Chung C; Martinez D; Sabari B; Margol AS; Panwalkar P; Parolia A; Pekmezci M; McEachin RC; Cieslik M; Tamrazi B; Garcia BA; La Rocca G; Santi M; Lewis PW; Hawkins C; Melnick A; David Allis C; Thompson CB; Chinnaiyan AM; Judkins AR; Venneti S
    Sci Transl Med; 2016 Nov; 8(366):366ra161. PubMed ID: 27881822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Understanding the Deadly Silence of Posterior Fossa A Ependymoma.
    Lin GL; Monje M
    Mol Cell; 2020 Jun; 78(6):999-1001. PubMed ID: 32559429
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epigenomic alterations define lethal CIMP-positive ependymomas of infancy.
    Mack SC; Witt H; Piro RM; Gu L; Zuyderduyn S; Stütz AM; Wang X; Gallo M; Garzia L; Zayne K; Zhang X; Ramaswamy V; Jäger N; Jones DT; Sill M; Pugh TJ; Ryzhova M; Wani KM; Shih DJ; Head R; Remke M; Bailey SD; Zichner T; Faria CC; Barszczyk M; Stark S; Seker-Cin H; Hutter S; Johann P; Bender S; Hovestadt V; Tzaridis T; Dubuc AM; Northcott PA; Peacock J; Bertrand KC; Agnihotri S; Cavalli FM; Clarke I; Nethery-Brokx K; Creasy CL; Verma SK; Koster J; Wu X; Yao Y; Milde T; Sin-Chan P; Zuccaro J; Lau L; Pereira S; Castelo-Branco P; Hirst M; Marra MA; Roberts SS; Fults D; Massimi L; Cho YJ; Van Meter T; Grajkowska W; Lach B; Kulozik AE; von Deimling A; Witt O; Scherer SW; Fan X; Muraszko KM; Kool M; Pomeroy SL; Gupta N; Phillips J; Huang A; Tabori U; Hawkins C; Malkin D; Kongkham PN; Weiss WA; Jabado N; Rutka JT; Bouffet E; Korbel JO; Lupien M; Aldape KD; Bader GD; Eils R; Lichter P; Dirks PB; Pfister SM; Korshunov A; Taylor MD
    Nature; 2014 Feb; 506(7489):445-50. PubMed ID: 24553142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elevated CXorf67 Expression in PFA Ependymomas Suppresses DNA Repair and Sensitizes to PARP Inhibitors.
    Han J; Yu M; Bai Y; Yu J; Jin F; Li C; Zeng R; Peng J; Li A; Song X; Li H; Wu D; Li L
    Cancer Cell; 2020 Dec; 38(6):844-856.e7. PubMed ID: 33186520
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TERT promoter mutation and chromosome 6 loss define a high-risk subtype of ependymoma evolving from posterior fossa subependymoma.
    Thomas C; Thierfelder F; Träger M; Soschinski P; Müther M; Edelmann D; Förster A; Geiler C; Kim HY; Filipski K; Harter PN; Schittenhelm J; Eckert F; Ntoulias G; May SA; Stummer W; Onken J; Vajkoczy P; Schüller U; Heppner FL; Capper D; Koch A; Kaul D; Paulus W; Hasselblatt M; Schweizer L
    Acta Neuropathol; 2021 Jun; 141(6):959-970. PubMed ID: 33755803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TULIPs decorate the three-dimensional genome of PFA ependymoma.
    Johnston MJ; Lee JJY; Hu B; Nikolic A; Hasheminasabgorji E; Baguette A; Paik S; Chen H; Kumar S; Chen CCL; Jessa S; Balin P; Fong V; Zwaig M; Michealraj KA; Chen X; Zhang Y; Varadharajan S; Billon P; Juretic N; Daniels C; Rao AN; Giannini C; Thompson EM; Garami M; Hauser P; Pocza T; Ra YS; Cho BK; Kim SK; Wang KC; Lee JY; Grajkowska W; Perek-Polnik M; Agnihotri S; Mack S; Ellezam B; Weil A; Rich J; Bourque G; Chan JA; Yong VW; Lupien M; Ragoussis J; Kleinman C; Majewski J; Blanchette M; Jabado N; Taylor MD; Gallo M
    Cell; 2024 Sep; 187(18):4926-4945.e22. PubMed ID: 38986619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular genetics of ependymomas and pediatric diffuse gliomas: a short review.
    Nobusawa S; Hirato J; Yokoo H
    Brain Tumor Pathol; 2014 Oct; 31(4):229-33. PubMed ID: 25182241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recurrent pediatric infratentorial ependymomas: a systematic review and meta-analysis on outcomes and molecular classification.
    Montgomery EY; Thirunavu V; Pagadala M; Shlobin NA; Plant-Fox AS; Lam S; DeCuypere M
    J Neurosurg Pediatr; 2023 Feb; 31(2):132-142. PubMed ID: 36433871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chromosome 1q gain and tenascin-C expression are candidate markers to define different risk groups in pediatric posterior fossa ependymoma.
    Araki A; Chocholous M; Gojo J; Dorfer C; Czech T; Heinzl H; Dieckmann K; Ambros IM; Ambros PF; Slavc I; Haberler C
    Acta Neuropathol Commun; 2016 Aug; 4(1):88. PubMed ID: 27550150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Posterior fossa ependymoma H3 K27-mutant: an integrated radiological and histomolecular tumor analysis.
    Mariet C; Castel D; Grill J; Saffroy R; Dangouloff-Ros V; Boddaert N; Llamas-Guttierrez F; Chappé C; Puget S; Hasty L; Chrétien F; Métais A; Varlet P; Tauziède-Espariat A
    Acta Neuropathol Commun; 2022 Sep; 10(1):137. PubMed ID: 36104744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.